A key enzyme's troubles in Japan threaten Advanced Enzyme's future

Market pulse

All eyes will be on the Reserve Bank of India's monetary policy committee meeting this week, with its interest rate decision due on August 5. Meanwhile, the corporate earnings season continues to gather pace as heavyweights like State Bank of India, Titan Company, Bharti Airtel, and ONGC are scheduled to report their quarterly results. Investors will also monitor global cues, including developments in the US-Iran conflict and signals from the Federal Reserve, for direction.

From the investor's mind

One post worth your time, explained

@soicfinance · on X

Generic Active Pharmaceutical Ingredient (API) realizations are increasing not due to reduced pricing pressure, but rather as a necessary pass-through of higher raw material costs. Ishmohit Arora of SOIC explains that solvent prices, a key raw material, have nearly doubled and in some cases tripled. This cost pass-through was essential for manufacturers to maintain viability.

Word in the street

What the wider market is buzzing about

Advanced Enzyme Technologies Limited

₹306Past year ▼ 12%M.cap ₹3,527 Cr

A key enzyme is drawing uncomfortable questions for Advanced Enzyme Technologies, a company with a market capitalization of roughly ₹3,527 crore. The stock has slid over 12 percent in the last year, and attention is turning to serratiopeptidase, one of its largest revenue and profit contributors. Observers noted that a major Japanese pharmaceutical company voluntarily took the enzyme off the market after studies failed to show its efficacy was greater than a placebo. This has raised concerns about the total market size for a product with questionable efficacy, even if it is considered safe. Advanced Enzyme, for its part, expects the enzyme to remain a major contributor and is also awaiting approval to be the sole supplier in the European Union.

Yesterday's big moves